Drug Discovery & DDS– category –
-
Drug Discovery & DDS
AI Drug Discovery’s Core Challenge: Not Data Volume, But Converting Data into Actionable Clinical Evidence
MedCity News USA Overview The real challenge in AI-driven drug discovery is not the abundance of data, but the ability to transform that data into meaningful 'evidence' while preserving clinical context. Robust scientific and regulatory ... -
Drug Discovery & DDS
Insilico Medicine and Saudi Aramco Unveil sorbaMOF DB to Accelerate AI-Driven MOF Discovery for DAC Technologies
Unibest Industrial Co., Ltd. International Overview Insilico Medicine, in collaboration with Saudi Aramco, has launched 'sorbaMOF DB,' a validated materials database with an interpretable AI framework designed to accelerate the discovery... -
Drug Discovery & DDS
AI Biotechs Drive ‘Fail-Fast’ Drug Development in Biopharma, Powered by DeepMind’s AlphaFold
BioSpace USA Overview AI-centric biotechs like Isomorphic Labs and Generate Biomedicines are leveraging Google DeepMind's AlphaFold and proprietary 'dataverses' to propel a 'fail-fast' approach in drug discovery through in silico experim... -
Drug Discovery & DDS
AI-Driven CRISPR Design: Revolutionizing Gene Editing with Enhanced Precision and Efficiency
Preprints.org International Overview A comprehensive review systematically investigates AI-driven tools and methodologies for CRISPR design, highlighting AI's role in significantly enhancing gene editing precision, efficiency, and automa... -
Drug Discovery & DDS
AI Compresses Drug Discovery Timelines from Years to Months, Insilico Medicine’s IPF Drug Advances to Phase 2 in 18 Months
MarketScale USA Overview Generative AI is dramatically shortening drug discovery timelines, reducing development from years to months. Insilico Medicine's platform successfully advanced a candidate compound for idiopathic pulmonary fibro... -
Drug Discovery & DDS
Isomorphic Labs: AI-Designed Drugs Head to Human Trials, Reshaping Pharma’s Future
Wired USA Overview Isomorphic Labs, a Google DeepMind spin-off, is on the verge of commencing human clinical trials for drugs entirely designed by artificial intelligence. Leveraging its foundational AlphaFold system, the company aims to... -
Drug Discovery & DDS
bioRxiv Unveils Joint Transcriptomic and Morphological Phenotype Modeling for Generative Molecular Design
bioRxiv International Overview A bioRxiv preprint details research on jointly modeling transcriptomic and morphological phenotypes for generative molecular design. This novel approach allows for the simultaneous consideration of gene exp... -
Drug Discovery & DDS
CAi Copilot Leverages Agentic AI for Intent-Driven Molecular Design, Reducing Operational Burden
arXiv USA Overview CAi Copilot introduces an agentic workflow system that translates researchers' intent into adaptive and traceable molecular computations, aiming to significantly reduce operational workload in early-stage molecular des... -
Drug Discovery & DDS
Scaffold-Aware Transformer Accelerates Novel Molecular Design with High Binding Affinity
PMC USA Overview Researchers have developed a novel scaffold-aware generative model, integrating transformers with graph attention networks, capable of efficiently designing new molecules with desired structural properties and high bindi... -
Drug Discovery & DDS
Drug Discovery & DDS Weekly Report August 9, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report August 09, 2026 (PDF) — Download Weekly Report August 09, 2026 (PDF) — DownloadDownload 🎙 Podcast August 09, ...